Literature DB >> 21671571

Structures of glycosylated mammalian glutaminyl cyclases reveal conformational variability near the active center.

David Ruiz-Carrillo1, Birgit Koch, Christoph Parthier, Michael Wermann, Tresfore Dambe, Mirko Buchholz, Hans-Henning Ludwig, Ulrich Heiser, Jens-Ulrich Rahfeld, Milton T Stubbs, Stephan Schilling, Hans-Ulrich Demuth.   

Abstract

Formation of N-terminal pyroglutamate (pGlu or pE) from glutaminyl or glutamyl precursors is catalyzed by glutaminyl cyclases (QC). As the formation of pGlu-amyloid has been linked with Alzheimer's disease, inhibitors of QCs are currently the subject of intense development. Here, we report three crystal structures of N-glycosylated mammalian QC from humans (hQC) and mice (mQC). Whereas the overall structures of the enzymes are similar to those reported previously, two surface loops in the neighborhood of the active center exhibit conformational variability. Furthermore, two conserved cysteine residues form a disulfide bond at the base of the active center that was not present in previous reports of hQC structure. Site-directed mutagenesis suggests a structure-stabilizing role of the disulfide bond. At the entrance to the active center, the conserved tryptophan residue, W(207), which displayed multiple orientations in previous structure, shows a single conformation in both glycosylated human and murine QCs. Although mutagenesis of W(207) into leucine or glutamine altered substrate conversion significantly, the binding constants of inhibitors such as the highly potent PQ50 (PBD150) were minimally affected. The crystal structure of PQ50 bound to the active center of murine QC reveals principal binding determinants provided by the catalytic zinc ion and a hydrophobic funnel. This study presents a first comparison of two mammalian QCs containing typical, conserved post-translational modifications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671571     DOI: 10.1021/bi200249h

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening.

Authors:  Mária Szaszkó; István Hajdú; Beáta Flachner; Krisztina Dobi; Csaba Magyar; István Simon; Zsolt Lőrincz; Zoltán Kapui; Tamás Pázmány; Sándor Cseh; György Dormán
Journal:  Mol Divers       Date:  2017-01-09       Impact factor: 2.943

2.  Structure of glutaminyl cyclase from Drosophila melanogaster in space group I4.

Authors:  Petr Kolenko; Birgit Koch; Jens Ulrich Rahfeld; Stephan Schilling; Hans Ulrich Demuth; Milton T Stubbs
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-03-28

3.  Molecular characterization of tick salivary gland glutaminyl cyclase.

Authors:  Steven W Adamson; Rebecca E Browning; Chien-Chung Chao; Robert C Bateman; Wei-Mei Ching; Shahid Karim
Journal:  Insect Biochem Mol Biol       Date:  2013-06-13       Impact factor: 4.714

4.  The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease.

Authors:  Flavio DiPisa; Cecilia Pozzi; Manuela Benvenuti; Matteo Andreini; Guido Marconi; Stefano Mangani
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-07-28       Impact factor: 1.056

5.  siRNA screen identifies QPCT as a druggable target for Huntington's disease.

Authors:  Michael Hannus; Birte Sönnichsen; Sara Imarisio; Angeleen Fleming; Maria Jimenez-Sanchez; Wun Lam; Alessia Tarditi; Fiona Menzies; Teresa Ed Dami; Catherine Xu; Eduardo Gonzalez-Couto; Giulia Lazzeroni; Freddy Heitz; Daniela Diamanti; Luisa Massai; Venkata P Satagopam; Guido Marconi; Chiara Caramelli; Arianna Nencini; Matteo Andreini; Gian Luca Sardone; Nicola P Caradonna; Valentina Porcari; Carla Scali; Reinhard Schneider; Giuseppe Pollio; Cahir J O'Kane; Andrea Caricasole; David C Rubinsztein
Journal:  Nat Chem Biol       Date:  2015-04-06       Impact factor: 15.040

6.  Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis.

Authors:  Nadine Taudte; Miriam Linnert; Jens-Ulrich Rahfeld; Anke Piechotta; Daniel Ramsbeck; Mirko Buchholz; Petr Kolenko; Christoph Parthier; John A Houston; Florian Veillard; Sigrun Eick; Jan Potempa; Stephan Schilling; Hans-Ulrich Demuth; Milton T Stubbs
Journal:  J Biol Chem       Date:  2021-01-08       Impact factor: 5.157

7.  Soluble variants of human recombinant glutaminyl cyclase.

Authors:  Cristiana Castaldo; Silvia Ciambellotti; Raquel de Pablo-Latorre; Daniela Lalli; Valentina Porcari; Paola Turano
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

8.  Transamidase subunit GAA1/GPAA1 is a M28 family metallo-peptide-synthetase that catalyzes the peptide bond formation between the substrate protein's omega-site and the GPI lipid anchor's phosphoethanolamine.

Authors:  Birgit Eisenhaber; Stephan Eisenhaber; Toh Yew Kwang; Gerhard Grüber; Frank Eisenhaber
Journal:  Cell Cycle       Date:  2014-04-17       Impact factor: 4.534

9.  OGlcNAcylation and phosphorylation have opposing structural effects in tau: phosphothreonine induces particular conformational order.

Authors:  Michael A Brister; Anil K Pandey; Agata A Bielska; Neal J Zondlo
Journal:  J Am Chem Soc       Date:  2014-03-04       Impact factor: 15.419

10.  Structural modelling of the lumenal domain of human GPAA1, the metallo-peptide synthetase subunit of the transamidase complex, reveals zinc-binding mode and two flaps surrounding the active site.

Authors:  Chinh Tran-To Su; Swati Sinha; Birgit Eisenhaber; Frank Eisenhaber
Journal:  Biol Direct       Date:  2020-09-29       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.